Formycon Pipeline Climbs To Six As It Adds Two Biosimilars

Partner Teva In Place For Ranibizumab Launch In UK And EU

Ahead of entering the planned commercialization stage for its first biosimilar product, German biotech Formycon has revealed a series of major announcements, including that it has beefed up its pipeline with an additional two new assets. Meanwhile, it expects to soon find a commercialization partner for its proposed Stelara biosimilar.

Arrows up (Sean Prior/Alamy Stock Photo)
2022 is set to be a landmark year for Formycon • Source: Shutterstock (Alamy Stock Photo)

German biosimilars developer Formycon AG has initiated development of an additional two undisclosed biosimilar projects, at the same time as it confirmed that its FYB201 biosimilar ranibizumab product Ongavia was still expected to be the first biosimilar Lucentis product marketed in Europe.

Amid a series of updates, Formycon has disclosed that for its two new biosimilar projects, FB208 and FYB209, “the reference...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.